| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal: ID6405: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease |
|
Medicine details |
|
| Medicine name | blinatumomab (Blincyto®) |
| Formulation | Intravenous injection |
| Reference number | 5366 |
| Indication | With chemotherapy for the treatment of patients with CD19-positive (CD19+), B-precursor ALL in the consolidation phase |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| NICE guidance | |